共 50 条
- [1] BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Maurice-Dror, CorinneTirosh, OsnatBen-Shabat, Sheerli KrugerEshar, ShiriPlolonsky, OmriDavis, NoaHaber, ElranMeshner, ShiriPerets, Ruth
- [2] Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Sacco, Joseph J.Harrington, Kevin JosephOlsson-Brown, AnnaChan, Tze Y.Nenclares, PabloLeslie, IslaBommareddy, PraveenXie, BenWolff, JohannesMiddleton, Mark R.
- [3] Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)BLOOD, 2017, 130Patnaik, Mrinal M.Sallman, David A.Sekeres, Mikkael A.Luger, SelinaBejar, RafaelHobbs, Gabriela S.DeZern, Amy E.Bolognese, JamesTraynor, MaryMishra, VishnuWages, DavidGualberto, AntonioScholz, CatherinePadron, Eric
- [4] Denosumab in the treatment of giant cell tumor of bone: preliminary results from an open-label phase 2 studyCLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 66 - 66Thomas, D.Chawla, S.Skubitz, K.Staddon, A.Henshaw, R.Smith, J.Ye, Z.Sohn, W.Jun, S.
- [5] Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialLANCET HAEMATOLOGY, 2020, 7 (09): : E660 - E670Diefenbach, Catherine S.Hong, FangxinAmbinder, Richard F.Cohen, Jonathan B.Robertson, Michael J.David, Kevin A.Advani, Ranjana H.Fenske, Timothy S.Barta, Stefan K.Palmisiano, Neil D.Svoboda, JakobMorgan, David S.Karmali, ReemSharon, EladStreicher, HowardKahl, Brad S.Ansell, Stephen M.
- [6] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harrington, Kevin JosephRullan, AntonioDeighton, LouiseBarata, JoaoCastro, HenryAhlers, Christoph MatthiasMcrae, JohnBommareddy, PraveenCoffin, Robert S.Middleton, Mark R.
- [7] Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 studyCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 1041 - 1049Tolcher, Anthony W.LoRusso, PatriciaArzt, JenniferBusman, Todd A.Lian, GuinanRudersdorf, Niki S.Vanderwal, Carol AnnWaring, Jeffrey F.Yang, JianningHolen, Kyle D.Rosen, Lee S.
- [8] Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 studyCancer Chemotherapy and Pharmacology, 2015, 76 : 1041 - 1049Anthony W. TolcherPatricia LoRussoJennifer ArztTodd A. BusmanGuinan LianNiki S. RudersdorfCarol Ann VanderwalJeffrey F. WaringJianning YangKyle D. HolenLee S. Rosen
- [9] An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker resultsANNALS OF ONCOLOGY, 2022, 33 (07) : S926 - S927Harrington, K. J.Sacco, J. J.Olsson-Brown, A.Chan, T.Nenclares, P.Leslie, I.Bommareddy, P.Ahlers, C.Wolff, J.Middleton, M. R.
- [10] PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAHAEMATOLOGICA, 2017, 102 : 222 - 222Witzig, T.Sokol, L.Jacobsen, E.Advani, R.Mondejar, R.Piris, M.Burrows, F.Melvin, C.Mishra, V.Scholz, C.Gualberto, A.